EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer

This publication has 62 references indexed in Scilit:

• A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease
  Cancer, 2003
• Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
  New England Journal of Medicine, 2002
• Erythropoietin therapy: Is there a place in advanced prostate cancer-related anemia?
  European Journal Of Cancer, 2001
• Early intervention with epoetin alfa treats anaemia and improves quality of life in ovarian cancer patients undergoing chemotherapy
  European Journal Of Cancer, 2001
• Erythropoietin reduces anemia and transfusions
  Cancer, 1999
• Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer
  British Journal of Cancer, 1999
• Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy
  Medical Oncology, 1998
• Prevention of chemotherapy‐induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double‐blind, randomized, phase III study)
  Transfusion, 1996
• Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
  New England Journal of Medicine, 1990
• EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSIS
  The Lancet, 1986